Smart pills could boost medication adherence for Alcohol-Related liver disease
NCT ID NCT07553377
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a digital pill system that tracks when people with alcohol-related liver disease take their medication (acamprosate) and provides personalized support to help them stay on track. The system includes a sensor in the pill, a wearable patch, and a smartphone app with coaching based on cognitive behavioral therapy. The goal is to see if this approach is feasible and acceptable for improving medication adherence and reducing heavy drinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acamprosate
What this could lead to
If successful, this could provide a new way to help people with alcohol-related liver disease stick to their medication, potentially improving treatment outcomes.
What could go wrong
This is a small, early feasibility study with only 50 participants, so results may not apply to everyone. The digital pill system may not be acceptable or easy to use for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale
New Haven, Connecticut, 06520, United States